Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Oral Paclitaxel for Patients with Advanced Solid Tumors
Details : INP12 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 19, 2024
Lead Product(s) : INP20
Therapeutic Area : Immunology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Oral Immunotherapy for Peanut Allergic Patients
Details : INP20 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Peanut Hypersensitivity.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
November 14, 2019
Lead Product(s) : INP20
Therapeutic Area : Immunology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable